GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of genuine question about TRIUMPH that I am slightly embarrassed to ask — 48 comments in the full submission. View in context.
4.6k
c/trialwatch·submitted 2 years ago by u/camila_vasquez

genuine question about TRIUMPH that I am slightly embarrassed to ask

Trial Databranch of 8 comments

The title is the whole question — genuine question about TRIUMPH that I am slightly embarrassed to ask — but here is why I am asking. Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one. The registered…

Read the full submission and all 48 comments →

This branch

8 comments, started 2 years ago
u/ewan_tulloch256 points·2 years ago

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

replysharereportpermalink
u/camila_vasquezOP146 points·2 years ago

That is the 68-week readout, not the 72-week one. Different trial, different duration.

replysharereportpermalink
u/cold_chromatogram31111 points·2 years ago

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

replysharereportpermalink
u/adaeze_weiss79 points·2 years ago

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

replysharereportpermalink
u/whois_wanda90 points·2 years ago

SURPASS is the diabetes programme and reports glycaemic endpoints

replysharereportpermalink
u/ferran_dahlberg116 points·2 years ago

intention to treat versus completers changes the number substantially

replysharereportpermalink
u/camila_vasquezOP64 points·2 years ago

Which trial, and which arm?

replysharereportpermalink
u/tove_ogunleye36 points·2 years ago

phase 2 finds a dose, phase 3 measures the effect

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →